Erlotinib/osimertinib/rociletinibAcquired drug resistance in metastatic lung adenocarcinoma: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1693卷 / 1期

关键词：

D O I：

10.1007/s40278-018-43090-y

中图分类号：

学科分类号：

摘要：

引用

页码：200 / 200

共 50 条

[41] Erlotinib/osimertinibAcquired clinical drug resistance: case report
Reactions Weekly, 2022, 1899 (1) : 185 - 185
[42] Metastatic lung adenocarcinoma to the bladder: A case report
Ye, Hai-Jun
Ma, Jian
Liu, Ying-Jie
Ye, Xiao-Fei
Zhang, Li-Wang
Li, Jin-Ge
ONCOLOGY LETTERS, 2015, 10 (03) : 1674 - 1676
[43] Erlotinib/osimertinib/selpercatinibAcquired resistance, diarrhoea and off-label use: case report
Reactions Weekly, 2021, 1871 (1) : 165 - 165
[44] Gefitinib/osimertinib/paclitaxelLack of efficacy and drug resistance: case report
Reactions Weekly, 2023, 1942 (1) : 136 - 136
[45] Carboplatin/osimertinib/pemetrexedNephrotoxicity and acquired drug resistance: case report
Reactions Weekly, 2021, 1879 (1) : 89 - 89
[46] Osimertinib/trametinibVarious toxicities along with drug resistance: case report
Reactions Weekly, 2019, 1777 (1) : 189 - 189
[47] Acquired resistance to osimertinib in advanced lung cancer: A case report
Xu, Jiayi
Xu, Zikai
Hong, Jianwei
Zhou, Xiaoyu
ASIAN JOURNAL OF SURGERY, 2024, 47 (08) : 3763 - 3764
[48] Carboplatin/osimertinib/pemetrexedFever, diarrhoea and drug resistance: case report
Reactions Weekly, 2023, 1970 (1) : 87 - 87
[49] Osimertinib/paclitaxelAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1842 (1) : 292 - 292
[50] The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
Kibirova, Albina
Mattes, Malcolm D.
Smolkin, Matthew
Ma, Patrick C.
CASE REPORTS IN ONCOLOGY, 2019, 12 (03): : 765 - 776

← 1 2 3 4 5 →